Epigenetic alternations concern heritable yet reversible changes in histone or DNA
modifications that regulate gene activity beyond the underlying sequence. Epigenetic …

The development and immune evasion of cancer stem cells (CSCs) limit the efficacy of
currently available anticancer therapies. Recent studies have shown that epigenetic …

Type I protein arginine methyltransferases (PRMTs) catalyze asymmetric dimethylation of
arginines on proteins. Type I PRMTs and their substrates have been implicated in human …

Aberrant cell proliferation is a hallmark of cancer, including glioblastoma (GBM). Here we
report that protein arginine methyltransferase (PRMT) 6 activity is required for the …

To better understand the impact of chromatin structure on regulation of the prostate cancer
transcriptome, we develop high-resolution chromatin interaction maps in normal and …

Protein arginine methyltransferase 6 (PRMT6) is a type I PRMT that is involved in epigenetic
regulation of gene expression through methylating histone or non-histone proteins, and …

In castration-resistant prostate cancer (CRPC), clinical response to androgen receptor (AR)
antagonists is limited mainly due to AR-variants expression and restored AR signaling. The …

Arginine methylation is a post-translational modification that plays pivotal roles in signal
transduction and gene transcription during cell fate determination. We found protein …

Arginine methylation is a ubiquitous posttranslational modification that regulates critical
cellular processes including signal transduction and pre-mRNA splicing. Here, we report …

PRMT6, a type I arginine methyltransferase, di-methylates the arginine residues of both
histones and non-histones asymmetrically. Increasing evidence indicates that PRMT6 plays …